Heavy Tau Burden with Subtle Amyloid β Accumulation in the Cerebral Cortex and Cerebellum in a Case of Familial Alzheimer’s Disease with APP Osaka Mutation
暂无分享,去创建一个
Yasuyoshi Watanabe | T. Suhara | M. Higuchi | A. Mawatari | Yasuhiro Wada | J. Kawabe | H. Shimada | T. Tomiyama | J. Takeuchi | Akitoshi Takeda | Y. Itoh | H. Shimada | Shinobu Minatani
[1] Yasuyoshi Watanabe,et al. Staging of tau distribution by positron emission tomography may be useful in clinical staging of Alzheimer disease , 2020 .
[2] T. Tomiyama,et al. APP Osaka Mutation in Familial Alzheimer’s Disease—Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance , 2020, International journal of molecular sciences.
[3] K. Servick. Doubts persist for claimed Alzheimer's drug. , 2019, Science.
[4] David T. Jones,et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.
[5] J. Attems,et al. Neuropathology and biochemistry of early onset familial Alzheimer’s disease caused by presenilin-1 missense mutation Thr116Asn , 2018, Journal of Neural Transmission.
[6] M. Mintun,et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease , 2018, The New England journal of medicine.
[7] Takashi Kato,et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Virginia M. Y. Lee,et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies , 2017, Brain : a journal of neurology.
[9] Ming-Rong Zhang,et al. Association between Aβ and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study , 2016, Alzheimer's & dementia.
[10] Y. Um,et al. Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro , 2016, Annals of Nuclear Medicine.
[11] Ming-Rong Zhang,et al. PET Quantification of Tau Pathology in Human Brain with 11C-PBB3 , 2015, The Journal of Nuclear Medicine.
[12] Lin Xie,et al. Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.
[13] Nick C Fox,et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria , 2014, The Lancet Neurology.
[14] A. Takashima,et al. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice , 2014, Acta Neuropathologica.
[15] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[16] H. Mori,et al. Clinical Course of Patients with Familial Early-Onset Alzheimer’s Disease Potentially Lacking Senile Plaques Bearing the E693Δ Mutation in Amyloid Precursor Protein , 2011, Dementia and Geriatric Cognitive Disorders.
[17] F. Lopera,et al. Deposition of Hyperphosphorylated Tau in Cerebellum of PS1 E280A Alzheimer's Disease , 2011, Brain pathology.
[18] W. Jagust,et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core , 2010, Alzheimer's & Dementia.
[19] Rie Teraoka,et al. A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.
[20] Wei Zhu,et al. Outcome over seven years of healthy adults with and without subjective cognitive impairment , 2010, Alzheimer's & Dementia.
[21] Shaomin Li,et al. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.
[22] Yasuyoshi Watanabe,et al. A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia , 2008, Annals of neurology.
[23] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[24] Carl W. Cotman,et al. Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.
[25] W. K. Cullen,et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.
[26] Martin N Rossor,et al. Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val→Ile) mutation cases: A morphometric investigation , 1996, Journal of the Neurological Sciences.
[27] Kenneth S. Kosik,et al. The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.
[28] A. Alavi,et al. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. , 1987, AJR. American journal of roentgenology.
[29] Emiliano Bruner,et al. The cerebellum in Alzheimer's disease: evaluating its role in cognitive decline. , 2018, Brain : a journal of neurology.
[30] D. Selkoe,et al. Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.